165 related articles for article (PubMed ID: 38797114)
21. Huo Xiang Zheng Qi Oral Liquid Combined with 5-HT3 Receptor Antagonists and Dexamethasone Can Prevent Chemotherapy-Induced Nausea and Vomiting for Patients Receiving Multiday Cisplatin-Based Regimen: A Multicenter Trial.
Wei H; Sun Y; Xie L; Jia Y; He J; Deng X; Huang W; Hu Y; Zhu J
J Integr Complement Med; 2023 Aug; 29(8):501-509. PubMed ID: 36999940
[No Abstract] [Full Text] [Related]
22. Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy.
Chasen M; Urban L; Schnadig I; Rapoport B; Powers D; Arora S; Navari R; Schwartzberg L; Gridelli C
Support Care Cancer; 2017 Jan; 25(1):85-92. PubMed ID: 27557833
[TBL] [Abstract][Full Text] [Related]
23. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC).
Zhang L; Lu S; Feng J; Dechaphunkul A; Chang J; Wang D; Chessari S; Lanzarotti C; Jordan K; Aapro M
Ann Oncol; 2018 Feb; 29(2):452-458. PubMed ID: 29092012
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
A Mahrous M; A El-Azab G; A Tawfik H
Cancer Chemother Pharmacol; 2021 Jul; 88(1):121-129. PubMed ID: 33835230
[TBL] [Abstract][Full Text] [Related]
25. Validation of different personalized risk models of chemotherapy-induced nausea and vomiting: results of a randomized, double-blind, phase III trial of fosaprepitant for cancer patients treated with high-dose cisplatin.
Zhao Y; Zhao B; Chen G; Chen Y; Liao Z; Zhang H; Feng W; Li Y; Weng H; Li W; Zhou Y; Ren B; Lu Y; Chen J; Liu Z; Su Z; Wang W; Zhang L
Cancer Commun (Lond); 2023 Feb; 43(2):246-256. PubMed ID: 36545810
[TBL] [Abstract][Full Text] [Related]
26. Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan.
Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
Int J Clin Oncol; 2017 Apr; 22(2):405-412. PubMed ID: 27909835
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of antiemetic practices for prevention of chemotherapy-induced nausea and vomiting (CINV): results of a European oncology nurse survey.
Dielenseger P; Börjeson S; Vidall C; Young A; Jahn P
Support Care Cancer; 2019 Nov; 27(11):4099-4106. PubMed ID: 30783815
[TBL] [Abstract][Full Text] [Related]
28. Real-World Treatment Outcomes, Healthcare Resource Use, and Costs Associated with Antiemetics Among Cancer Patients on Cisplatin-Based Chemotherapy.
Navari RM; Nelson WW; Shoaib S; Singh R; Zhang W; Bailey WL
Adv Ther; 2023 Jul; 40(7):3217-3226. PubMed ID: 37245189
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance).
Kottschade L; Novotny P; Lyss A; Mazurczak M; Loprinzi C; Barton D
Support Care Cancer; 2016 Jun; 24(6):2661-7. PubMed ID: 26768436
[TBL] [Abstract][Full Text] [Related]
30. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
Natale JJ
Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
[TBL] [Abstract][Full Text] [Related]
31. Two doses of fosaprepitant included prophylactic treatment for the three-day cisplatin-based chemotherapy induced nausea and vomiting.
Li Y; Wan Y; Yang X; Chen P; Gui Y; He L; Xie Y; Tian J; Duan P; Liu G; Sun Y; Zhu J
J Cancer Res Clin Oncol; 2024 Jun; 150(6):290. PubMed ID: 38836908
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of antiemetic in reducing chemotherapy-induced nausea and vomiting in adult patients; An oncology center experience.
Al-Salloum HF; Al-Harbi HE; Abdelazeem A
J Oncol Pharm Pract; 2023 Sep; 29(6):1317-1325. PubMed ID: 36518002
[TBL] [Abstract][Full Text] [Related]
33. Comparative clinical effectiveness of various 5-HT3 RA antiemetic regimens on chemotherapy-induced nausea and vomiting associated with hospital and emergency department visits in real world practice.
Hatoum HT; Lin SJ; Buchner D; Cox D
Support Care Cancer; 2012 May; 20(5):941-9. PubMed ID: 21533811
[TBL] [Abstract][Full Text] [Related]
34. A nurse-led evidence-based practice project to monitor and improve the management of chemotherapy-induced nausea and vomiting.
Underhill ML; Chicko L; Berry DL
Clin J Oncol Nurs; 2015 Feb; 19(1):38-40. PubMed ID: 25689647
[TBL] [Abstract][Full Text] [Related]
35. Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice.
Affronti ML; Schneider SM; Herndon JE; Schlundt S; Friedman HS
Support Care Cancer; 2014 Jul; 22(7):1897-905. PubMed ID: 24570103
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic effect of low frequency electric pulse therapy on cisplatin-based chemotherapy-induced nausea and vomiting in patients with lung adenocarcinoma: A prospective controlled study.
Hu M; Yao L; Li L; Han Y; Wang Y; Lei Z; Wu H
Medicine (Baltimore); 2022 Aug; 101(34):e30088. PubMed ID: 36042582
[TBL] [Abstract][Full Text] [Related]
37. Prolonged administration of aprepitant improves cisplatin-based chemotherapy-induced nausea and vomiting.
Li Y; Sun Y; Liu B; Sun Y; Chen P; Xie K; Wang Y; Zhu J
Future Oncol; 2022 Jun; 18(20):2533-2543. PubMed ID: 35587019
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
Oyama K; Fushida S; Kaji M; Takeda T; Yabushita K; Nezuka H; Kinami S; Kadoya N; Takai Y; Tsukioka Y; Ohyama S; Tsuji K; Tsukada T; Kinoshita J; Fujimura T; Ohta T
Int J Clin Oncol; 2016 Jun; 21(3):483-90. PubMed ID: 26507140
[TBL] [Abstract][Full Text] [Related]
39. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
[TBL] [Abstract][Full Text] [Related]
40. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
